Bioasis Technologies teams up with Aposense for siRNA delivery research

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) announced it has formed a research collaboration with Aposense Limited, an Israeli bio-pharmaceutical company specializing in development of novel drugs utilizing membrane electrical forces.

Bioasis said the research partnership will focus on the delivery of small interfering RNA (siRNA) into the brain.

“The non-invasive delivery of genetic therapies such as siRNA into the brain has proved challenging. Neurological diseases affect over a billion people worldwide and to address this challenge Bioasis has developed a revolutionary technology that delivers effective treatments across the blood-brain barrier,” Bioasis Executive Chair Dr Deborah Rathjen said in a statement.  

READ: Bioasis Technologies reveals research validating its blood brain barrier deliver platform to improve neurological function 

“With the recent publication of data demonstrating efficacy associated with xB 3 -siRNA knock-down of the NOX4 gene in a model of stroke, we are pleased to have formed this collaboration with Aposense and we look forward to progressing the discovery and development of new siRNA-based drugs incorporating our xB 3 platform, enabling the treatment of serious neurological conditions.” Dr. Rathjen added.

Aposense CEO Yuval Gottenstein also commented, stating: “siRNA therapeutics for central nervous system disorders holds the potential to address devastating diseases of great unmet medical need, and an immediate expansion area for Aposense.

“Accordingly, we are thrilled to incorporate our vast know how in the design and delivery of siRNA-based drugs with the xB 3 BBB delivery platform developed by Bioasis.”

Scientists at Bioasis have worked for over a decade to develop the patented xB3 platform, which helps small molecules shuttle across the BBB safely. Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing compounds into the brain. In a nutshell, the xB3 platform uses a small peptide to ferry molecules across the BBB in a process called receptor-mediated transcytosis.

Contact Sean at [email protected]

Story by ProactiveInvestors